Lipocine (NASDAQ:LPCN) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Lipocine (NASDAQ:LPCN) to a sell rating in a report released on Saturday morning.

LPCN has been the subject of a number of other reports. HC Wainwright reissued a “buy” rating and set a $15.00 price target (up from $7.00) on shares of Lipocine in a research report on Wednesday, January 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Lipocine currently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Lipocine Stock Up 10.0%

Shares of NASDAQ:LPCN opened at $8.49 on Friday. The firm has a 50 day moving average of $6.88 and a 200 day moving average of $4.35. The company has a market capitalization of $47.14 million, a price-to-earnings ratio of -8.32 and a beta of 0.99. Lipocine has a 52 week low of $2.52 and a 52 week high of $12.37.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings results on Thursday, November 6th. The specialty pharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). The company had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.24 million. Lipocine had a negative net margin of 126.67% and a negative return on equity of 30.65%.

Hedge Funds Weigh In On Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Citadel Advisors LLC bought a new stake in Lipocine Inc. (NASDAQ:LPCN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 14,247 shares of the specialty pharmaceutical company’s stock, valued at approximately $41,000. Citadel Advisors LLC owned approximately 0.26% of Lipocine as of its most recent SEC filing. Institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.